EUVIMEDEUVIMED entdecken
Crossref

Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross‐sectional study

Charles Ragusa, Bruno Pereira, David Balayssac iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.35006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Charles Ragusa und 2 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U1107, NEURO-DOL, Université Clermont Auvergne, Direction de la Recherche Clinique et de l'Innovation, CHU Clermont-Ferrand, Clermont-Ferrand,…. Hauptthemen laut MEDLINE: Cancer Survivors, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Institut National Du Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pain is a prevalent symptom among cancer patients and survivors. Psychoactive substance use (PSU) is associated with both the presence and severity of pain. However, little is known about this association in the context of cancer. The primary objective was to compare the prevalence of PSU and its relationship with pain during and after cancer. PSU was defined as the use of nonmedication substances (alcohol, tobacco, e‐cigarettes, cannabidiol, and cannabis), with frequency categorized as at least yearly, monthly, weekly, or daily. Secondary objectives aimed to explore the relationships between PSU and pain characteristics, health‐related quality of life, anxiety, depression, deprivation, and individual characteristics. Among the 1041 individuals included, pain prevalence was 44.7% (95% confidence interval [CI] 41.6%–47.8%). The overall prevalence of PSU at least monthly was 67.0% (95% CI 64.0%–69.8%). The proportions of chronic and neuropathic pains were higher for at least monthly use of cannabidiol compared to nonuse (70.0% vs. 39.3% and 55.7% vs. 28.1%, p < .001). In multivariate analysis, the monthly uses of tobacco and cannabidiol were higher in painful individuals than in nonpainful ones (odds ratio: 2.85 [95% CI 1.22–6.64] and 3.76 [95% CI 1.13–12.44], p < .05). From the point of view of the patient care, the study underscores the need for physicians to prioritize smoking cessation and pay attention to the use of cannabidiol during and after cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer SurvivorsNeoplasmsHumansMaleFemaleCross-Sectional StudiesMiddle AgedFranceAgedAdultPrevalenceQuality of LifePsychotropic DrugsCancer PainSubstance-Related DisordersPain

Stichwörter der Autor:innen

cancercannabidiolcannabispaintobacco

Substanzen

Psychotropic Drugs

Autor:innen und Institutionen

  • INSERM U1107, NEURO-DOL, Université Clermont Auvergne, Direction de la Recherche Clinique et de l'Innovation, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Direction de la Recherche Clinique et de l'Innovation, CHU Clermont-Ferrand, Clermont-Ferrand, France.

ORCID-Profile: David Balayssac

Förderung

  • Institut National Du Cancer

Zitieren

APA

Ragusa, C., Pereira, B., & Balayssac, D. (2024). Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross‐sectional study. International Journal of Cancer. https://doi.org/10.1002/ijc.35006

Vancouver

Ragusa C, Pereira B, Balayssac D. Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross‐sectional study. International Journal of Cancer. 2024. doi:10.1002/ijc.35006

BibTeX
@article{Ragusa2024,
  author = {Ragusa, Charles and Pereira, Bruno and Balayssac, David},
  title = {Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross‐sectional study},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.35006}
}
Kostenlos starten →